Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

Marco L. Davila, M.D., Ph.D.

Assistant Professor of Medicine
Hematologist/Oncologist

  • Appointments
    615-936-8580
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Division of Hematology/Oncology
    615-322-4967

    Nashville Veterans Affairs Medical Center
    615-327-4751

    Office
    615-936-7887
  • Faxes
    Division of Hematology/Oncology Fax
    615-343-7602
    Nashville Veterans Affairs Medical Center Fax
    615-873-7901

    Clinic Fax
    615-343-7602
  • Addresses
    Clinic
    Division of Hematology/Oncology
    2220 Pierce Avenue
    777 Preston Research Building
    Nashville, TN 37232-6307

    Division of Hematology/Oncology
    2220 Pierce Ave, 777 PRB
    Nashville, TN 37232-6307
    Website

    Nashville Veterans Affairs Medical Center
    1310 24th Ave. South
    Nashville , TN 37212-2637
    Website

    Office
    Division of Hematology/Oncology
    2220 Pierce Avenue
    518 Preston Research Building
    Nashville, TN 37232-6307
Profile

Dr. Marco Davila is a medical oncologist who specializes in the treatment of patients with cancer. Dr. Davila has a particular interest in patients with hematologic malignancies such as chronic lymphocytic leukemia (CLL), B cell Acute Lymphoblastic Leukemia (B-ALL), and Acute Myeloid Leukemia (AML).
Read more ....

Dr. Marco Davila is a medical oncologist who specializes in the treatment of patients with cancer. Dr. Davila has a particular interest in patients with hematologic malignancies such as chronic lymphocytic leukemia (CLL), B cell Acute Lymphoblastic Leukemia (B-ALL), and Acute Myeloid Leukemia (AML). As a translational physician-scientist, he is engaged in both clinical and laboratory research involving these malignancies. Dr. Davila's laboratory develops gene-engineered cell therapies that target cancer cells in animal models of hematologic malignancies. The goal of this laboratory research is to identify optimal cell therapies that can then be evaluated in patients with cancer. As a former Principal Investigator of a clinical trial using genetically engineered T cells targeted against malignant B cells, he witnessed the potential for this as a cancer immunotherapy. It's Dr. Davila's hope that his innovative laboratory and clinical research here at Vanderbilt will lead to similar therapeutic options for patients with other cancers that are not responsive to standard chemotherapy.

Education

 

  • Duke University School of Medicine, MD
  • Duke University Graduate School, PhD (Immunology)